Exosomes: Current Clinical Applications and Future Directions

Extracellular Vesicles (Exosomes): Current Clinical Applications and Future Directions - Single Course

.75 CME CREDITS – $65.00

Exosomes (extracellular vesicles) and their applications represent the newest frontier in clinical medicine. This session will explore the historical discovery of exosomes, how and where they are generated. Early clinical results for treatment of osteoarthritis, pain, hair restoration, COPD, CHF, pulmonary artery hypertension and age related decline will be presented. Future directions for exosome clinical applications will discuss the status of current IRB studies and opportunities for interested clinicians to collaborate to advance the science of exosome treatments.

CME

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Age Management Medicine Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM for physicians and 8.00 contact hours for nurses and 8.00 of knowledge/ -based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.


Objectives – After attending this program you should be able to:

  1. Learn and understand the evidence-based science behind the use of Exosomes as an adjunct to an Age Management Medicine practice in the areas of biomarkers, ways of treating disease and use of targeted delivery vehicles for therapeutic molecules.
  2. Learn essential scientific information for the use of Exosomes in Age Management Medicine and how to clinically apply this knowledge to individualized treatment plans to improve outcomes.
  3. Understand how Exosomes can be applied clinically to various areas such as cardiac health, cancer, retinal and optic nerve conditions and gastrointestinal diseases.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book and have disclosed they have no relevant financial relationships.

Ian White, Ph.D.
Chief Scientific Officer, IMAC Regeneration Centers, Miami, FL
Chairman of the Scientific Committee, American Academy of Stem Cell Physicians
President, BioFirma, LLC
FACULTY DISCLOSURE:
IMAC Regeneration Centers: Scientific/Medical Advisory Board Member

Kathy O’Neil Smith, M.D.
Private Internal, Integrative and Regenerative Medicine Practice, Newton, MA
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

George Shapiro, M.D.
Adjunct Assistant Professor Clinical Medicine, New York Medical College, Valhalla, NY
Founding Partner, Cenegenics, New York City
Member, AMMG Conference Planning Committee
FACULTY DISCLOSURE:
Organicell:Scientific/Meical Advisory Board Member, Organicell Stockholder, Cellularity: Scientific / Medical Advisory Board Member

Marvin Sponaugle, M.D.
Founder & President, North Pinellas Anesthesia, Oldsmar, FL
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Paul Thompson, M.D.
Private Practice, Fort Worth, TX
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

Daniel Sperling, M.D.
Medical Director & Chief of Interventional Uroradiology, Sperling Prostate Center, Florida & New York
Medical Director, Sperling Medical Group, Florida
Medical Director, Sperling Neurosurgery Associates, Florida
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

Jeffrey Weiss, M.D.
Staff, Department of Surgery, North Broward Medical Center, Pompano Beach, FL
Board of Directors & Staff, Park Creek Surgery Center, Coconut Creek, FL
Staff, Al Zahra Hospital, Al Barsha, Dubai, U.A.E.
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Edwin Lee, M.D.
Assistant Professor of Internal Medicine, University of Central Florida, College of Medicine, Orlando, FL
Founder, Institute for Hormonal Balance, Orlando, FL
Member, AMMG Conference Planning Committee
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

Rebecca Murray, APRN, FNP-BC, CDE
Endocrine Nurse Practitioner, Institute for Hormonal Balance, Orlando, FL
Medical Director, Ward-Murray HealthCare Consulting, Groton, CT
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Michale “Mickey” Barber, M.D.
CEO, CMO, Better Life Carolinas, Charleston, SC
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed

William Kapp III, M.D., MS, FAAOS
Founder, Chairman/CEO, Longevity Bioimaging/Landmark Hospitals, Naples, FL
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Release Date: January 15, 2020
Expiration Date: December 31, 2021

Learning Objectives:

  1. Explain the evidence-based science behind the use of Exosomes as an adjunct to an Age Management Medicine practice in the areas of biomarkers, ways of treating disease and use of targeted delivery vehicles for therapeutic molecules.
  2. Learn essential scientific information for the use of Exosomes in Age Management Medicine and how to clinically apply this knowledge to individualized treatment plans to improve outcomes.
  3. Understand how Exosomes can be applied clinically to various areas such as cardiac health, cancer, retinal and optic nerve conditions and gastrointestinal diseases.

SPECIAL OFFER

This course is part of the Exosomes: The Next Generation of Biologic Medicine bundle.
Purchase the complete series and save!

COURSE MENU

ACCOUNT MENU

NEED HELP?

FACULTY

Kapp, William K. III - M.D., MS, FAAOS
  • Founder, Chairman/CEO, Longevity Bioimaging/Landmark Hospitals, Naples, FL

William Kapp III, M.D., MS, FAAOS

Dr. William Kapp received his B.S. in Biochemistry from the University of Georgia and his M.S. in Immunology and M.D. at the Medical College of Georgia, where he graduated with honors and was inducted into Alpha Omega Alpha, the medical honor society. He attended the Baylor College of Medicine in Houston, Texas for residency in Orthopaedic Surgery and completed his specialty training in 1994. Dr. Kapp is a board-certified orthopaedic surgeon and a Fellow in the American Academy of Orthopaedic Surgeons, licensed to practice in Illinois, Missouri, Texas and Georgia. He has served on the Board of Directors of the Missouri Orthopaedic Association and has been chair of the Legislative Affairs Committee. Until 2005, he served as flight surgeon in the US Air Force Reserves with the rank of Major. Dr. Kapp served as managing partner and leader for Physicians Alliance Surgery Center in Cape Girardeau and was instrumental in its design, development, and certification. He served as its Founding President and Medical Director from 2000 – 2003 and on its Medical Board from 2000 − 2011. Physicians Alliance is a multi-specialty outpatient surgical center with four operating suites and over 30 staff members. In 2011, St. Francis Medical Center acquired partial interest in Physicians Alliance. Dr. Kapp also served 15 years as managing partner for Orthopaedic Associates of SE Missouri, the region’s only orthopaedic center. Orthopaedic Associates is a 9-physican practice with over 70 employees. Under his direction, the group grew from five physicians and two offices to nine physicians and five satellite locations. Revenue grew over 300% under his leadership. Dr. Kapp had a vision to establish regional referral centers for medically complex patients requiring hospital-based post-acute care. Landmark Hospitals has grown into seven regional referral centers. Under his leadership, Landmark has implemented new information technologies that allow clinicians to easily document patient encounters and then follow and manage the patient upon discharge from our critical care hospitals across all post-acute settings, allowing for better outcomes and a seamless continuum of care. Dr. Kapp is a founding advisory board member of Missouri Physicians Mutual. MPM was founded in the late 1990’s as a Missouri-based 383 company to provide affordable medical malpractice insurance to a troubled market. MPM was able to grow from 10 physicians at its inception to well over 2,000, becoming the largest insurer in the state for physician medical malpractice insurance.

Buy this Course